CO2020012484A2 - Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") - Google Patents
Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")Info
- Publication number
- CO2020012484A2 CO2020012484A2 CONC2020/0012484A CO2020012484A CO2020012484A2 CO 2020012484 A2 CO2020012484 A2 CO 2020012484A2 CO 2020012484 A CO2020012484 A CO 2020012484A CO 2020012484 A2 CO2020012484 A2 CO 2020012484A2
- Authority
- CO
- Colombia
- Prior art keywords
- triazacyclododecanesulfonamide
- tcd
- protein secretion
- based protein
- secretion inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Aquí se proporcionan inhibidores de la secreción de proteínas basados en triazaciclododecansulfonamida ("TCD"), tales como inhibidores de Sec61, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos para usar los mismos. Por ejemplo, aquí se proporcionan compuestos de Fórmula (I): (I) y sales y composiciones farmacéuticamente aceptables que incluyen las mismas. Los compuestos descritos aquí pueden usarse, por ejemplo, en el tratamiento de enfermedades que incluyen inflamación y/o cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643931P | 2018-03-16 | 2018-03-16 | |
| US201962803704P | 2019-02-11 | 2019-02-11 | |
| PCT/US2019/022533 WO2019178510A1 (en) | 2018-03-16 | 2019-03-15 | Triazacyclododecansulfonamide ("tcd")-based protein secretion inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020012484A2 true CO2020012484A2 (es) | 2020-10-30 |
Family
ID=66041635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0012484A CO2020012484A2 (es) | 2018-03-16 | 2020-10-06 | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11578055B2 (es) |
| EP (1) | EP3765447B1 (es) |
| JP (1) | JP2021518337A (es) |
| KR (1) | KR20200133238A (es) |
| CN (1) | CN112262129B (es) |
| AU (1) | AU2019236248B2 (es) |
| BR (1) | BR112020018767A2 (es) |
| CA (1) | CA3093972A1 (es) |
| CL (1) | CL2020002398A1 (es) |
| CO (1) | CO2020012484A2 (es) |
| DK (1) | DK3765447T3 (es) |
| ES (1) | ES2953139T3 (es) |
| FI (1) | FI3765447T3 (es) |
| HR (1) | HRP20230804T1 (es) |
| HU (1) | HUE062455T2 (es) |
| IL (1) | IL277252A (es) |
| JO (1) | JOP20200233A1 (es) |
| LT (1) | LT3765447T (es) |
| MA (1) | MA52008A (es) |
| MX (1) | MX2020009645A (es) |
| PE (1) | PE20210926A1 (es) |
| PH (1) | PH12020551493A1 (es) |
| PL (1) | PL3765447T3 (es) |
| PT (1) | PT3765447T (es) |
| RS (1) | RS64524B1 (es) |
| SG (1) | SG11202008841VA (es) |
| SI (1) | SI3765447T1 (es) |
| TW (1) | TWI818962B (es) |
| WO (1) | WO2019178510A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663161A (en) * | 1995-02-17 | 1997-09-02 | The Research Foundation Of State University Of New York | Anti-viral triaza compounds |
| WO2002080856A2 (en) * | 2001-04-06 | 2002-10-17 | University And Community College System Of Nevada On Behalf Of The University Of Nevada, Reno | Triaza compound immunoregulatory agents |
-
2019
- 2019-03-15 HU HUE19715609A patent/HUE062455T2/hu unknown
- 2019-03-15 HR HRP20230804TT patent/HRP20230804T1/hr unknown
- 2019-03-15 PL PL19715609.4T patent/PL3765447T3/pl unknown
- 2019-03-15 SI SI201930602T patent/SI3765447T1/sl unknown
- 2019-03-15 CN CN201980032763.5A patent/CN112262129B/zh active Active
- 2019-03-15 MA MA052008A patent/MA52008A/fr unknown
- 2019-03-15 AU AU2019236248A patent/AU2019236248B2/en active Active
- 2019-03-15 WO PCT/US2019/022533 patent/WO2019178510A1/en active Application Filing
- 2019-03-15 LT LTEPPCT/US2019/022533T patent/LT3765447T/lt unknown
- 2019-03-15 CA CA3093972A patent/CA3093972A1/en active Pending
- 2019-03-15 EP EP19715609.4A patent/EP3765447B1/en active Active
- 2019-03-15 RS RS20230647A patent/RS64524B1/sr unknown
- 2019-03-15 US US16/979,457 patent/US11578055B2/en active Active
- 2019-03-15 BR BR112020018767-4A patent/BR112020018767A2/pt unknown
- 2019-03-15 JP JP2020548935A patent/JP2021518337A/ja active Pending
- 2019-03-15 JO JOP/2020/0233A patent/JOP20200233A1/ar unknown
- 2019-03-15 MX MX2020009645A patent/MX2020009645A/es unknown
- 2019-03-15 TW TW108108893A patent/TWI818962B/zh active
- 2019-03-15 SG SG11202008841VA patent/SG11202008841VA/en unknown
- 2019-03-15 PE PE2020002281A patent/PE20210926A1/es unknown
- 2019-03-15 FI FIEP19715609.4T patent/FI3765447T3/fi active
- 2019-03-15 ES ES19715609T patent/ES2953139T3/es active Active
- 2019-03-15 DK DK19715609.4T patent/DK3765447T3/da active
- 2019-03-15 PT PT197156094T patent/PT3765447T/pt unknown
- 2019-03-15 KR KR1020207029261A patent/KR20200133238A/ko active Search and Examination
-
2020
- 2020-09-09 IL IL277252A patent/IL277252A/en unknown
- 2020-09-15 PH PH12020551493A patent/PH12020551493A1/en unknown
- 2020-09-16 CL CL2020002398A patent/CL2020002398A1/es unknown
- 2020-10-06 CO CONC2020/0012484A patent/CO2020012484A2/es unknown
-
2022
- 2022-05-11 US US17/741,989 patent/US20220402891A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| CL2021000972A1 (es) | Inhibidores de la proteína tirosina fosfatasa | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CO2017008862A2 (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina | |
| UY37098A (es) | Moduladores de ror-gamma | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| BR112022000155A2 (pt) | Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma | |
| AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação |